General Information of the Drug (ID: M6APDG03528)
Name
SX-ARPC
Synonyms
ADR-L09; Androgen receptor antagonists (small peptide mimetic, androgen independent prostate cancer),Serometrix
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D0C1UP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Androgen receptor (AR)
ETS-related transcription factor Elf-3 (ELF3)
In total 1 mechanisms lead to this potential drug response
Response Summary Androgen receptor (AR) is a therapeutic target for SX-ARPC. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of SX-ARPC through regulating the expression of Androgen receptor (AR). [1], [2]
References
Ref 1 ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.
Ref 2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.